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Abstract
A spectrum of intrapulmonary airway diseases, for example,
cigarette smoke–induced bronchitis, cystic fibrosis, primary ciliary
dyskinesia, and non–cystic fibrosis bronchiectasis, can be
categorized as “mucoobstructive” airway diseases. A common theme
for these diseases appears to be the failure to properly regulate
mucus concentration, producing mucus hyperconcentration that
slows mucus transport and, importantly, generates plaque/plug
adhesion to airway surfaces. These mucus plaques/plugs generate
long diffusion distances for oxygen, producing hypoxic niches
within adherent airway mucus and subjacent epithelia. Data suggest
that concentrated mucus plaques/plugs are proinflammatory, in part
mediated by release of IL-1a from hypoxic cells. The infectious
component of mucoobstructive diseases may be initiated by
anaerobic bacteria that proliferate within the nutrient-rich hypoxic
mucus environment. Anaerobes ultimately may condition mucus to
provide the environment for a succession to classic airway
pathogens, including Staphylococcus aureus, Haemophilus
influenzae, and ultimately Pseudomonas aeruginosa. Novel therapies
to treat mucoobstructive diseases focus on restoring mucus
concentration. Strategies to rehydrate mucus range from the
inhalation of osmotically active solutes, designed to draw water
into airway surfaces, to strategies designed to manipulate the
relative rates of sodium absorption versus chloride secretion to
endogenously restore epithelial hydration. Similarly, strategies
designed to reduce the mucin burden in the airways, either by
reducing mucin production/secretion or by clearing accumulated
mucus (e.g., reducing agents), are under development. Thus, the new
insights into a unifying process, that is, mucus hyperconcentration,
that drives a significant component of the pathogenesis of
mucoobstructive diseases promise multiple new therapeutic
strategies to aid patients with this syndrome.
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include a complex of diseases characterized
by cough and sputum production, airflow
obstruction, airway inflammation, and
intermittent/continuous infection. Cystic
fibrosis (CF) is the prototype of such
diseases, but others would include cigarette
smoke–induced chronic bronchitis,
primary ciliary dyskinesia, and non-
CF bronchiectasis. The common
pathophysiological cascade describing these
diseases reflects abnormalities of airway
epithelial ion transport and/or increased
mucin secretion that produce mucus
dehydration, mucus stasis, and ultimately
airway inflammation and bacterial infection.
The ion transport abnormalities that
produce airway surface dehydration differ
per disease, with CF being perhaps the
best-described mechanism (1). Therapies
designed to specifically restore function of
the mutant cystic fibrosis transmembrane
conductance regulator (CFTR) have become
available (2–5). However, pharmacological
therapies for this disease syndrome/cascade
do not exist. Inhaled hypertonic saline and
mannitol are “hydrator” therapies used for
some of these diseases but not for others
(6–8). Elucidation of the mechanisms and
pathways that produce this syndrome
promises to provide therapeutic targets to
aid in the care of this patient population.
Mucus Plugging Triggers Sterile
Inflammation inMucoobstructive
Lung Diseases
Mucus plugging has long been recognized
as providing a strong stimulus for the
neutrophilic airway inflammation and a
nutrient-rich nidus for the bacterial
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infections that are characteristic of
mucoobstructive lung diseases such as
CF and chronic obstructive pulmonary
disease (COPD) (9). Over the past decade,
observational studies from the Australian
Respiratory Early Surveillance Team for
Cystic Fibrosis (AREST CF) cohort have
convincingly shown that neutrophilic
airway inflammation is already present in
many infants and young children with CF,
often in the absence of detectable bacterial
infection (10, 11). However, the concept of
“inflammation in the absence of bacterial
infection” of mucus-obstructed airways has
remained controversial.
In this context, emerging data from
independent animal models support the
concept that mucus plugging per se can
trigger airway inflammation in the absence
of bacterial infection (12). First, a series
of studies in mice with airway-specific
overexpression of the b subunit of the
epithelial sodium channel (bENaC-Tg),
producing a CF-like increase in airway
sodium/fluid absorption, demonstrated that
airway surface dehydration is sufficient to
produce early-onset mucus plugging and
the full spectrum of mucoobstructive lung
disease, including chronic neutrophilic
airway inflammation, goblet cell metaplasia,
increased mucin (Muc5b and Muc5ac)
production, and emphysema-like structural
lung damage (13–18). This mucoobstructive
phenotype, including spontaneous airway
inflammation, was observed not only
under conventional specific pathogen–free
conditions but also when bENaC-Tg mice
were raised in a germ-free vivarium (19).
Second, studies in CF ferrets treated life-
long with antibiotics demonstrated that
bacterial infection is not required for CF-
like mucoinflammatory disease featuring
airway mucus plugging, neutrophilic
inflammation, and bronchiectasis in this
model (20). Third, a comparison of the
pulmonary phenotypes of the bENaC-Tg
mouse and the Muc5b-deficient mouse
indicated that excess mucus/mucus adhesion
may be more important than mucociliary
dysfunction alone in the in vivo pathogenesis
of chronic airway inflammation (21, 22).
These studies showed that Muc5b is crucial
for mucociliary clearance (MCC) and that
Muc5b-deficient mice feature more severe
mucociliary dysfunction than bENaC-Tg
mice, but no mucus plugging. However,
despite a more severe impairment in
MCC, Muc5b-deficient mice exhibited
modest airway inflammation and structural
lung damage compared with bENaC-Tg
mice (21).
Studies in bENaC-Tg mice have
provided clues regarding the mechanistic
links between mucus plugging and sterile
airway inflammation. These studies
demonstrated that mucus plugging is
associated with cellular hypoxia and
necrosis of epithelial cells lining the airways
(16). Necrotic cell death due to hypoxia is a
well-known and potent stimulus of sterile
neutrophilic inflammation, and previous
studies identified activation of IL-1 receptor
(IL-1R) signaling by the alarmin IL-1a that
is released from necrotic cells as a key
mechanism in this process (23).
These observations triggered more
detailed investigations of the role of IL-1R
signaling in the pathogenesis of neutrophilic
inflammation in mucoobstructive lung
disease (24). It was shown that genetic deletion
of IL-1R, as well as pharmacological inhibition
with the endogenous IL-1 receptor antagonist
anakinra, largely inhibited neutrophilic
inflammation and structural lung damage in
bENaC-Tg mice (24). In addition, evaluation
of lung sections from patients with CF and
COPD detected necrotic airway epithelial
cells in mucus-obstructed airways and found
that the numbers of these necrotic cells
correlated with the severity of mucus
obstruction in the small airways of patients
with CF and COPD (24). These findings
were also corroborated by an association
study in various CF cohorts, suggesting the
IL-1R locus as a genetic modifier of CF (25).
Collectively, these data demonstrate
that airway surface dehydration plays an
important role in the in vivo pathogenesis of
mucus plugging and support emerging
concepts that 1) accumulated (adherent)
airway mucus per se is proinflammatory in
the absence of bacterial infection; 2) mucus
plugging can trigger the full spectrum of
mucoobstructive lung disease in vivo;
and 3) hypoxic cell death, triggering IL-1R
signaling, may play an important role in the
pathogenesis of sterile neutrophilic airway
inflammation and may serve as a novel
target for antiinflammatory therapy in
mucoobstructive lung diseases such as CF
and COPD (Figure 1) (12, 26).
Infectious Component of
Mucoobstructive Diseases
The infections associated with
mucoobstructive lung diseases typically
involve bronchial/bronchiolar airways.
Multiple interesting features characterize
this form of airway infection. First, the
bacterial infections almost exclusively
represent infections of mucus adherent to
airway surfaces (27). Biofilms may form as
a part of the mucus infection, but are
usually not found on epithelial surfaces.
Second, mucus plaques/plugs on airway
surfaces create niches of reduced oxygen
concentration, favoring infection by
organisms that gain energy efficiently under
anaerobic conditions (28–30). Third, many
of the infections of airway surfaces are
polymicrobial, including a mix of multiple
anaerobic and aerobic bacteria in varying
densities and distributions (31–34). Fourth,
many of these diseases are initiated by
aspiration of upper airway commensals
into a lower airway environment of
static/hypoxic mucus (32). Fifth, the
hyperconcentrated adherent mucus
generates very “tight” mucus meshes
(pores, 10 nm) that tend to shield bacteria
growing within mucus masses from
penetration, capture, and killing by
intraluminal polymorphonuclear cells (35).
Finally, airway disease and infection tend to
be heterogeneous, with areas of severe
disease (e.g., bronchiectasis) juxtaposed to
functionally normal airway regions (11, 26).
Data have revealed important new
insights into 1) mechanisms for the
acquisition of bacterial infection early in the
pathogenesis of mucoobstructive lung
disease; and 2) the response of airway
epithelia in health and disease to the
combined stresses of bacterial and host
defense products associated with bacterial
infection. Both examples have evolved from
studies of CF, perhaps the most studied of
the mucoobstructive diseases with respect to
infection.
It has been reported that the CF lung
environment early in life is characterized by
heterogeneous areas of hyperconcentrated,
adherent (static) mucus that have zones of
frank hypoxia and potentially mucus-
stimulated inflammation (Figure 2A).
Studies from the AREST-CF cohort suggest
that there may be a sequence of bacterial
infections that is superimposed on this CF
lower airway environment (Figure 2B) (32).
Specifically, after a period of relative sterility,
perhaps lasting 1–2 years, the environment
becomes invaded by strictly anaerobic
bacteria that appear to be aspirated from
the oropharynx. Subsequently, bacteria
known as “classic” CF pathogens invade
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this environment and likely dominate
the environment based on absolute
bacterial densities. Early classic CF
pathogenic bacteria again may be
commensal bacterial in the upper airways,
including Staphylococcus, Haemophilus
influenzae, and Moraxella. An interesting
speculation is that anaerobic bacteria in
a hypoxic mucin-rich environment
secrete endo/ecto-glycosidases to harvest
saccharides frommucin side chains to gain
energy by fermentation. Not only does
fermentation provide energy for anaerobic
bacteria, but it also may provide novel
substrates for the growth of the classic CF
pathogens (36).
Once established, pathogenic bacterial
infections persist in mucus plaques and
plugs laden with activated neutrophils and
macrophages (17, 37). This mixture of
liberated novel bacterial and leukocyte
products induces a complex reaction by the
host airway epithelium. Experimentally,
responses of airway epithelia to bacterial/
host products can be measured by exposing
normal and CF airway cultures to a
supernatant of the mucopurulent material
(SMM) extracted from CF lungs excised at
transplantation (Figure 3A). Comparisons
of the responses of normal airway epithelia
with CF airway epithelia to SMM revealed
that 1) both genotypes exhibited similar
mucin (MUC5AC and MUC5B) secretory
responses to SMM; 2) normal airway
epithelia exhibited ion transport responses
to SMM that included inhibition of
ENaC-mediated Na1/fluid absorption
and acceleration of CFTR-mediated Cl2
secretion, whereas CF airway epithelia
responded to SMM with neither an
inhibition of ENaC-mediated Na1/fluid
absorption nor CFTR-mediated Cl2/fluid
secretion; 3) confocal airway surface liquid
(ASL) height measurements detected an
increase in Cl2/fluid secretion as an increase
in ASL height in normal airway epithelia,
whereas the absence of ENaC regulation/
CFTR-mediated Cl2 secretion in
CF produced no change in ASL height
in CF airway epithelia; and 4) the increase
in mucin secretion, accompanied by a
relatively larger fluid secretion, diluted the
percent solids content of the mucus lining
normal human bronchial epithelial culture
surfaces, whereas the selective increase
in mucin secretion, in the absence of an
acceleration in fluid secretion, produced
an inappropriate hyperconcentration of CF
mucus (38, 39).
These data are informative because
they illustrate that the normal airway
epithelial response to bacterial infections is
dominated by the ability to actively secrete
more mucin, trap infecting bacteria, and
secrete a large fluid bolus onto epithelial
surfaces to accelerate mucociliary clearance
and “flush” bacteria off normal pulmonary
surfaces (Figure 3B, part I). Of note, a
similar coordinate upregulation of epithelial
mucin and fluid secretion is also observed in
response to allergen challenge, where it may
play an important role in efficient allergen
clearance to protect the host from chronic
allergic airway diseases such as asthma
(40–42). In contrast, the paradoxical and
inappropriate CF responses to bacterial
infection, that is, secreting mucins without
secreting fluid, hyperconcentrates mucus
and promotes mucus adhesion to CF airway
surfaces, limiting the effectiveness of both
cilial and cough-dependent mechanisms to
clear mucus from airway surfaces (Figure 3B,
part II) (38, 39). Thus, this paradoxical
CF response can in part explain how the
development of bacterial pathogenic
infections in CF airways accelerates the
rate of decline of lung function in patients
with CF.
Therapeutics
Therapeutic Targeting of Mucus
Plugging
Current therapeutic approaches to





















Figure 1. Mucus plugging causes hypoxic epithelial necrosis that triggers sterile inflammation in mucoobstructive lung disease. Mucus plugging produces
regional hypoxia and necrosis of a subset of epithelial cells lining the airway surfaces. Dying epithelial cells release the alarmin IL-1a into the airway
lumen. Binding of IL-1a to IL-1 receptors (IL-1Rs) on neighboring cells results in activation of the IL-1R/MyD88 signaling pathway, inducing neutrophilic
airway inflammation in the absence of bacterial infection. Image courtesy of Joshua Bird. MyD88 =myeloid differentiation primary response 88; NF-kB =
nuclear factor-kB; pO2 = partial pressure of oxygen.
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mucoobstructive lung diseases fall into three
broad categories: 1) hydrating strategies,
including both inhaled osmotically active
agents (hypertonic saline, mannitol) and
ion channel modulators, are designed to
“dilute” hyperconcentrated, diseased
mucus (43, 44) and to restore effective
mucus clearance; 2) mucin production/
secretion modifiers are predicted to lower
the mucus load and, hence, concentration
in the airways (45) and potentially restore
the MUC5AC:MUC5B ratio, which has
been demonstrated to be significantly
altered in disease (46); and 3) improved
mucolytics that directly modify the structure
of the mucus gel and improve rheological
properties of accumulated/adherent mucus
to aid clearance of accumulated mucus from
the lung.
Hypertonic Saline
Hypertonic saline was established more
than a decade ago as being clinically
effective in CF, as reflected in modest
improvements in pulmonary function and
an approximately 50% reduction in
pulmonary exacerbations (6, 47). Despite
the fact that studies at that time revealed
hypertonic saline accelerated mucus
clearance in patients with CF, the precise
mechanisms of hypertonic saline actions
and principles for clinical administration
of hypertonic saline have remained
controversial. Specifically, questions have
arisen as to whether hypertonic saline
exhibits actions to 1) electrostatically shield
charges on mucins and accelerate their
transport (48); 2) produce persistent
airway epithelial cell volume reductions
with inhibition of ENaC-mediated fluid
transport (49); or 3) osmotically draw
water onto airway surfaces and dilute/
rehydrate adherent hyperconcentrated
mucus (47). In part, these contrasting
hypotheses emerged from in vitro
protocols that typically employed large
bolus liquid additions to airway surfaces to
simulate the administration of hypertonic
saline.
Goralski and colleagues reported
the actions of (7%, wt/vol) aerosolized
hypertonic saline delivered to human
bronchial epithelial cultures covered by
a normally hydrated mucus layer (2%
solids) versus a CF-like dehydrated mucus
layer (12% solids) (50). Aerosol deposition
rates were designed to mimic clinical



























Figure 2. Early infection in the cystic fibrosis (CF) lung. (A) Predicted sequence of bacterial pathogen acquisition in early CF. The CF airway
early in life (left) has heterogeneous areas characterized by a hypoxic mucoinflammatory environment dominated by adherent mucus (green).
Aspiration (middle) introduces oral anaerobic pathogens into the lung. Oral anaerobes survive and proliferate in lower airway hypoxic mucus,
in part by fermenting sugars cleaved from mucins. With time and environmental exposure (right), classic CF pathogens (Staphylococcus
and Pseudomonas) infect adherent CF mucus. Fermentation products of mucins may promote classic pathogen infection. (B) Relative
abundance of bacteria in the bronchoalveolar lavage of infants/children with CF, as a function of age. Bacteria were binned into three classes:
1) environmental bacteria (green); 2) oral anaerobes (purple); and 3) classic CF pathogens (pink). Image courtesy of Bryan Zorn and Matthew
Wolfgang.
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Figure 3. Response of normal versus cystic fibrosis (CF) airway epithelia to bacterial infection. (A, part I) Response of normal (white columns) versus CF (red
columns) human bronchial epithelial cultures to luminal application of supernatant of mucopurulent material (SMM) harvested from lumens of CF airways.
Shown are total mucin secretion rates in response to SMM. (A, part II) Short-circuit current (Isc) profiles of Na
1 absorption (amiloride-sensitive Isc) and cystic
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Several points relevant to the mechanism
of hypertonic saline emerged from
those studies. First, confocal microscopy
revealed that administration of hypertonic
saline osmotically drew water onto airway
surfaces and, indeed, the mucus layer.
Interestingly, the relative rates of aerosol
deposition versus the rates of passive water
movement onto airway surfaces in
response to hypertonic saline aerosol
deposition produced an ASL osmolality
during hypertonic saline administration of
approximately 370 mOsm. Second, the
hydrating effects of hypertonic saline were
maximal at the initiation of aerosol
administration and terminated
immediately on cessation of delivery.
Active epithelial Na1 and fluid absorption
were identified as the processes that
removed hypertonic saline at the cessation
of delivery and, hence, controlled the
durability of hypertonic saline hydrating
effects. Finally, mucus on airway
surfaces produced profound effects on
responses to aerosolized hypertonic saline.
Particularly striking was the capacity of
hyperconcentrated mucus on airway
surfaces to substantially extend the
durability of hypertonic saline hydrating
effects. It is likely that a hyperconcentrated
mucus layer, with its high mucus
osmotic pressure, provided a counterforce
to active sodium transport–generated ion-
based osmotic pressures that slowed the
net absorption of water from airway
surfaces. Interestingly, the relative
duration of the effects of hypertonic saline
in a normal versus CF-like hypertonic
mucus environment mimicked reports
from in vivo MCC measurements that
described a relatively short period of
action of hypertonic saline in normal
subjects (,1 h) versus a more durable
response (.4 h) in subjects with cystic
fibrosis (51, 52).
Ion Channel Modulators
The introduction of CFTR repair therapies
has extended the hydration concept and
represents one of the most significant
advances in the treatment of CF (53).
Furthermore, these agents have also
confirmed the pathological significance of
mucus plugging and failed mucus clearance
in CF lung disease. Ivacaftor (VX-770;
Kalydeco), a “potentiator” of CFTR
function, has demonstrated impressive
improvements in lung function and
exacerbation frequency in patients with the
channel gating mutation G551D (2, 3). In
preclinical studies, ivacaftor improved
airway epithelial anion secretion, which
resulted in an enhanced volume of fluid on
airway surfaces (4). This finding translated
into improved CFTR channel activity in
patients, enhanced rates of mucociliary
clearance, and reduced mucus plugging of
small airways (54, 55). In the wake of the
success of ivacaftor, numerous alternative
CFTR therapies have been developed,
which include not only potentiators for
channel gating mutations, but also CFTR
“correctors” to improve trafficking of
mutated CFTR channels (e.g., F508del) to
the plasma membrane (Table 1). At least
20 candidate drugs, which are described as
CFTR modulators, are presently in clinical
development for the treatment of CF.
The utility of CFTR repair therapy may
well not be limited to the treatment of CF. At
least two CFTR potentiator compounds,
ivacaftor and QBW251, have been tested
in small, pilot COPD trials (56, 57). The
ivacaftor study suggested that there may be
the potential for improvements in CFTR
function (nasal potential difference and
sweat chloride) (56), although the study was
underpowered to detect definitive changes.
The QBW251 study reported improvements
in FEV1 and sweat chloride (58). These are
small, early studies, and additional, larger
trials will be necessary to understand
whether promoting CFTR function will be
of benefit to patients with COPD.
Beyond CFTR, additional airway ion
channels may represent important drug
targets to deliver hydration to the airway,
including TMEM16A (ANO-1), SLC26A9,
and the epithelial sodium channel, ENaC
(59). These CFTR “mutation agnostic”
approaches are likely to be important add-
on therapies for patients with CF already
treated with CFTR repair drugs and also
for subjects with CF with mutations not
amenable to the current CFTR repair
pipeline. Furthermore, these therapies
would also have the potential to expand
into therapies for the broad class of
mucoobstructive lung disease.
TMEM16A is a calcium-activated
chloride channel (CaCC) that is expressed in
the airway epithelium (60–62). More than
20 years ago, a CaCC was described in
the airway that was capable of eliciting a
significant anion secretory response in vivo
when stimulated with calcium-mobilizing
ligands such as ATP and UTP (63, 64). This
CaCC-mediated effect regulates anion and
fluid secretion in response to the mechanical
stresses imposed on the lungs during
breathing (65). Furthermore, this system is
able to maintain mucus clearance in the
absence of CFTR function in the early years
of CF. It is also noteworthy that both exercise
and chest physical therapy, maneuvers
that improve clinical outcomes, enhance
calcium signaling in the airway epithelium,
thereby regulating ion/fluid transport
mechanisms and promotingmucus clearance
(66–68). A therapy that would potentiate
the activity of TMEM16A is predicted to
enhance the fluid secretory capacity of airway
epithelia and mimic a CFTR potentiator–like
phenotype.
SLC26A9, a member of the solute
carrier 26 family, may also contribute to
Figure 3. (Continued). fibrosis transmembrane conductance regulator (CFTR) Cl2 secretion (forskolin-induced Isc) responses to SMM. (A, part III) Change in
airway surface liquid height in response to SMM. (A, part IV) Change in mucus concentration (% solids) in response to SMM (38). (B, part I) Normal epithelia:
Airway epithelia in basal state (left) coordinate mucin secretion rates and epithelial Na1 channel–mediated Na1/liquid absorption versus cystic fibrosis
transmembrane/Ca21-activated Cl2 channel (CaCC, i.e., TMEM16a) Cl2/liquid secretion to maintain mucus at an approximately 2% solids hydration state
commensurate with robust mucociliary clearance (MCC) rates. The balance of liquid transport and mucin secretion is maintained by ATP and adenosine
interaction with apical P2Y2 and A2b purinoceptors, respectively. Epithelial responses to bacterial/host products include mucin secretion, which via
corelease with mucins of adenosine (and AMP) stimulates a disproportionate increase in CFTR-mediated Cl2/fluid secretion, “super”-hydration of mucus
(1.5% solids), and accelerated MCC. The net effect is to flush bacteria off airway surfaces. (B, part II) CF: Under basal, that is, the “nondiseased” but
vulnerable, state (left), CF airway epithelia manage to maintain quasi-normal mucus hydration via upregulation of CaCC activity to offset missing CFTR Cl2
transport and unregulated Na1 absorption. In response to a bacterial/host product challenge, mucin secretion is upregulated, but the absence of CFTR
negates a coupled adenosine-mediated fluid secretory response. The net effect is to increase CF mucus concentration, slow MCC, and lead to spread/
worsening of CF airway disease. Image 3B courtesy of Joshua Bird. A2BR=A2B adenosine receptor; ADO= adenosine; ASL = airway surface liquid; ENaC =
epithelial Na1 channel; P2Y2R= purinergic receptor P2Y2; PBS= phosphate-buffered saline; PCL= perciliary layer.
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anion and fluid secretion in the airway
epithelium (69–71). SLC26A9 has been
demonstrated to transport chloride ions
through both CFTR-dependent and
independent mechanisms, although a
paucity of specific pharmacological tools
has limited our understanding of its
function. Genetic evidence supports
SLC26A9 as a disease modifier in CF, and
model systems have demonstrated a
significant role of this anion channel in
the regulation of mucus hydration (72).
Upregulation of Slc26a9 expression in
airway inflammation protects mice from
airway mucus plugging, while knockout
animals show a severe plugging phenotype
(40, 41). Pharmacological tools are
required to enable a better evaluation
of the therapeutic potential of activators
of this alternative chloride channel.
Inhaled ENaC blockers for the
treatment of CF lung disease have been
explored for more than 30 years but without
robust evidence of clinical efficacy (73).
Inhaled amiloride has been tested in several
long-term studies and has failed to show
reproducible improvements in lung
function, potentially due to a short duration
of action in the airway combined with the
dose-limiting side effect of hyperkalemia
(74). So is ENaC an invalid target for the
treatment of CF lung disease or have we not
yet found the right drug candidate?
What does not appear to be in question
is the target validation. Patients with loss-of-
function mutations in ENaC subunits have a
salt-wasting disease, pseudohypoaldosteronism
type 1, but also exhibit accelerated rates
of airway mucociliary clearance (75),
and inhaled amiloride accelerates
mucociliary clearance in clinical studies
(76). Further, airway-specific overexpression
of bENaC to phenocopy the increased
sodium transport characteristic of CF airways
resulted in CF-like lung disease in
mice (15, 77).
To this end, several groups have
explored the discovery of novel inhaled
ENaC blockers with a long duration of
action in the lung. One example,
VX-371, has demonstrated a durable
acceleration of MCC in animal models but
failed to show an improvement in FEV1 in a
28-day study in CF (78). Unfortunately,
Table 1. Cystic fibrosis transmembrane conductance regulator potentiators and correctors in drug development pipeline
Company Drug Name Mechanism Indication Route Clinical
Vertex Ivacaftor CFTR potentiator CF Oral Phase 3: EVOLVE (F508del/F508del), .4% FEV1
Tezacaftor CFTR corrector Phase 3: EXPAND (residual CFTRmutation/F508del),
.6.8% FEV1
Novartis QBW251 CFTR potentiator CF, COPD Oral Phase 2 CF: Less sweat chloride and more lung
function in heterozygous patients with CF with a
gating or residual function mutation. F508del/
F508del, no evidence of pharmacodynamics effect
Phase 2 COPD: (4 wk, 90 patients, LCI)
Galapagos GLPG1837 CFTR potentiator CF Oral Phase 2: SAPHIRA 1 (G551D), z30-mmol reduction
in sweat chloride, .5.4% ppFEV1
AbbVie Phase 2: SAPHIRA 2 (S1251N) completed?
Galapagos/AbbVie GLPG2222 CFTR corrector (C1) CF Oral Phase 2: ALBATROSS (CFTR gating mutation/
F508del, 35 patients, safety, tolerability, sweat
chloride)
Vertex VX-152 CFTR correctors CF Oral Phase 2: Triple combination: VX-152, tezacaftor,
ivacaftor in 60 patients with minimal function CFTR
mutation/F508del (8 wk), .9.7% FEV1 at 2 wk
VX-440 2nd generation Phase 2: Triple combination: VX-440, tezacaftor,
ivacaftor in 200 patients with minimal function
CFTR mutation/F508del (16 wk), .12.0% FEV1
at 4 wk
VX-659 Orkambi Phase 1: .9.6% FEV1
Concert/Vertex CTP-656 CFTR potentiator
Deuterated
ivacaftor
CF Oral Phase 2: CFTR gating mutations, 4 wk, 40 patients,
sweat chloride, FEV1
ProQR QR010 CFTR stimulator
RNAi
CF Inhaled Phase 1b: Safety, tolerability, and pharmacokinetics,
64 patients with CF, F508del/F508del. Phase 1b:
Safety, tolerability, and pharmacokinetics, 18
patients with CF, F508del homozygous or
heterozygous
Galapagos/AbbVie GLPG2451 CFTR potentiator CF Oral Phase 1
Galapagos/AbbVie GLPG3067 CFTR potentiator CF Oral Phase 1
Galapagos/AbbVie GLPG2451 CFTR potentiator CF Oral Phase 1
Galapagos/AbbVie GLPG2737 CFTR corrector (C2) CF Oral Phase 1
Proteostasis PTI-428 CFTR amplifier CF Oral Phase 1
Proteostasis PTI-801 CFTR corrector CF Oral Phase 1
Flatley Discovery Labs FDL-169 CFTR corrector CF Oral Phase 1
Flatley Discovery Labs FDL-176 CFTR corrector CF Oral Phase 1
Galapagos/AbbVIe GLPG2851 CFTR corrector CF Oral Preclinical
Proteostasis PTI-808 CFTR potentiator CF Oral Preclinical
Definition of abbreviations: CF = cystic fibrosis; CFTR = cystic fibrosis transmembrane conductance regulator; COPD = chronic obstructive pulmonary
disease; FEV1 = forced expiratory volume in 1 second; LCI = lung clearance index; ppFEV1 = percent predicted FEV1; RNAi = RNA interference.
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this study failed to report any evidence of
target engagement at the evaluated dose,
precluding any further assessment of the
validity of ENaC as a therapeutically useful
drug target. In addition to direct blockers of
the channel, alternative approaches to
negatively regulate ENaC function by either
gene silencing (antisense oligonucleotides)
or channel internalization (SPX-101) are
also being explored (79, 80). SPX-101 is a
peptide derivative of a region of SPLUNC-1
(BPIFA1), which has been reported to
stimulate the internalization of the ENaC
subunits, thereby reducing sodium transport.
Inhaled dosing has been reported to
increase tracheal mucus velocity in sheep
and to improve survival in the bENaC-
overexpressing mouse (80), and is currently
in phase 2a trials. Critical to understanding
whether ENaC is a viable target to deliver
clinical benefit will be well-designed clinical
studies with biomarkers to establish whether
channel function has been attenuated in
parallel with the clinical endpoints.
Reduced Mucin Synthesis and
Secretion
Reducing the quantity of mucus in the
lumen of the airways could theoretically
be achieved by either 1) reducing the
number of mucin-producing (goblet) cells;
2) inhibiting the pathways regulating mucin
biosynthesis; or 3) inhibiting the secretion of
packagedmucins, that is, prevent exocytosis.
There are currently no such therapies
available, although recent data have
suggested that the combination of
corticosteroids and b2-adrenoreceptor
agonists may have a modest effect on airway
goblet cell numbers in vitro (81).
Historically, much attention has been
afforded to the epidermal growth factor
receptor (EGFR) pathway in the regulation
of airway goblet cell formation (82).
Numerous preclinical models, both in vitro
and in vivo, suggested a key role for this
pathway in airway epithelial mucin biology.
However, more recent clinical data with the
EGFR antagonist BIBW 2948 BS failed to
show any changes in airway mucin markers
in patients with COPD despite evidence of
target engagement in a 28-day study (83).
The compound was not well tolerated, and it
is likely that alternative candidates will be
required to further test this target hypothesis.
More recently, the role of the
Notch pathway in the regulation of airway
epithelial differentiation has become clear.
In addition to a developmental role,
Notch signaling also appears to regulate the
heterogeneity of the cell populations in
the adult airway epithelium. Studies using
antibodies to antagonize either Notch
receptors or ligands have implicated roles
for the Notch2 receptor and Jagged ligands
in the maintenance of goblet cell populations
in both primary human cells and murine
models (84, 85). Strategies to control Notch
pathway activation may represent a novel
approach to attenuate excessive mucus
production in the lungs. However, which
diseases and patient subpopulations may
benefit from this approach will require early
proof-of-concept studies.
A number of additional pathways and
targets have been proposed to regulate
goblet cell formation. Candidates include
MAPK13, GABAA antagonists, and CLCA1
inhibitors (45), although the literature and
patent filings do not support these being
actively pursued for therapeutic benefit.
Reducing goblet cell exocytosis may also
provide benefit in a mucus-hyperproducing
and -hypersecreting airway (86).
Approaches such as purinergic P2Y2
receptor antagonism have been proposed,
and candidates such as the MARCKS
peptide have shown efficacy in preclinical
systems (45). However, to date no candidate
compounds or targets have percolated
through to clinical testing. As our molecular
understanding of the mechanisms
controlling goblet cell exocytosis expands,
understanding the pathways regulating
baseline (tonic) secretion and stimulated
secretion may be important for ensuring
that the mucociliary apparatus can maintain
function while limiting excessive secretion,
particularly in the small airways (87). For
example, in the Munc13-22/2mouse, where
baseline mucin secretion from club cells was
attenuated (88), significant increases in
stored mucins, likely available for stimulated
secretion, were observed. If suddenly
released, this large bolus of mucin could
represent a safety concern. Further studies
with therapeutic candidates will be required
to define the safety implications associated
with attenuating goblet cell exocytosis
and whether it will be essential to only
influence the pathways regulating stimulated
secretion to avoid a potential stockpiling of
secretory vesicles.
Mucolytics
Inhaled DNase is a “mucolytic” that cleaves
extracellular DNA and reduces sputum
viscosity (89). It is a mainstay for CF
therapy, but its efficacy appears restricted to
this patient population. Carbocysteine and
N-acetylcysteine, focused onmucin disulfide
bond reduction, have been used for many
years to treat mucoobstructive lung disease
with evidence of only limited efficacy (90,
91). Data have challenged the biochemical
efficacy and potency of these agents to
remodel the mucus gel to improve its
transport properties. To this end, novel,
more potent disulfide bond mucin-reducing
agents with properties to enable efficient
inhaled dosing may have the potential to
deliver clinical benefit. Compounds such
as P3001, a potent reducing agent with
an extended duration of action in the
airway lumen, are showing evidence of
efficacy both in in vitro mucus transit
models as well as in vivo models of
mucus obstruction (92, 93).
Conclusion
There is an emerging database describing
the causes and consequences of mucus
accumulation, adhesion, and obstruction in
intrapulmonary airways. A unifying theme
appears to be that mucus hyperconcentration,
that is, dehydration, produces a failure
of mucus transport and, ultimately, the
adherent mucus plaques that trigger the
inflammation and infection associated
with these diseases. Disease-specific
therapies aimed at the individual
pathogenic processes that initiate mucus
hyperconcentration, for example, CFTR-
dependent defects in ion transport/airway
surface hydration, are models for therapies
of this class of diseases. However, until
specific disease pathways are identified for
each disease, more general strategies to
reduce airway mucus concentrations by
hydration therapies and/or therapies
designed to reduce/slow mucin secretion
appear rational. The wide spectrum of
approaches to achieve this therapeutic
goal provides encouragement that novel
and more effective therapies for the
mucoobstructive diseases will be available
relatively soon. n
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